TY - JOUR
T1 - Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy
T2 - A single-institution historical experience
AU - Kantarjian, Hagop
AU - O'Brien, Susan
AU - Jabbour, Elias
AU - Garcia-Manero, Guillermo
AU - Quintas-Cardama, Alfonso
AU - Shan, Jenny
AU - Rios, Mary Beth
AU - Ravandi, Farhad
AU - Faderl, Stefan
AU - Kadia, Tapan
AU - Borthakur, Gautam
AU - Huang, Xuelin
AU - Champlin, Richard
AU - Talpaz, Moshe
AU - Cortes, Jorge
PY - 2012/3/1
Y1 - 2012/3/1
N2 - A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP. In CP, the 8-year survival was ≤ 15% before 1983, 42%-65% from 1983-2000, and 87% since 2001. Survival was worse in older patients (P ∇ .004), but this was less significant since 2001 (P ∇ .07). Survival by Sokal risk was significantly different before 2001 (P <.001), but not since 2001 (P ∇ .4). In AP, survival improved over time (P < .001); the 8-year survival in patients treated since 2001 was 75%. Survival by age was not different in years < 2001 (P ∇ .09), but was better since 2001 in patients ≤ 70 years of age (P ∇ .004). In BP, the median survival improved over time (P < .001), although it has been only 7 months since 2001. In summary, survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML. Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML.
AB - A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP. In CP, the 8-year survival was ≤ 15% before 1983, 42%-65% from 1983-2000, and 87% since 2001. Survival was worse in older patients (P ∇ .004), but this was less significant since 2001 (P ∇ .07). Survival by Sokal risk was significantly different before 2001 (P <.001), but not since 2001 (P ∇ .4). In AP, survival improved over time (P < .001); the 8-year survival in patients treated since 2001 was 75%. Survival by age was not different in years < 2001 (P ∇ .09), but was better since 2001 in patients ≤ 70 years of age (P ∇ .004). In BP, the median survival improved over time (P < .001), although it has been only 7 months since 2001. In summary, survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML. Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML.
UR - http://www.scopus.com/inward/record.url?scp=84857731311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857731311&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-08-358135
DO - 10.1182/blood-2011-08-358135
M3 - Article
C2 - 22228624
AN - SCOPUS:84857731311
SN - 0006-4971
VL - 119
SP - 1981
EP - 1987
JO - Blood
JF - Blood
IS - 9
ER -